secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001854270-22-000041
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Bio reports Q3 net loss of $16.6M; cash $114.9M; SENTI-202 and SENTI-301A IND filings on track for 2023
--------------------------------------------------------------------------------

- Net loss $16.6M ($0.38/share) for Q3 2022; R&D expenses $8.1M, G&A $10.8M.
- Cash and equivalents $114.9M as of Sep 30, 2022; expected cash runway into 2024.
- SENTI-202 IND on track for 2023; Phase 1 trial planned for CD33/FLT3+ hematologic malignancies including AML and MDS.
- Selected SENTI-301A development candidate for GPC3+ solid tumors including HCC; IND expected in 2023.
- Preclinical data for SENTI-301A and SENTI-401 presented at SITC; SENTI-202 data to be presented at ASH Dec 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000185427022000041/0001854270-22-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000185427022000041/snti-20221110.htm
  HTML page:      https://secwatch.observer/filing/0001854270-22-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer